Strategic activation unites best-in-class
technology with end-to-end development solutions to optimize
therapeutic development process
Integrated DNA Technologies (IDT), a global leader in CRISPR
genome editing solutions, inked a licensing agreement with SeQure
Dx, a company focused on off-target analysis for preclinical and
clinical gene modification customers, bolstering IDT’s complete
CRISPR portfolio comprised of world-class RUO to CGMP solutions
from design to analysis. The licensing agreement enables IDT to
support cell and gene therapy developers through all phases of
their CRISPR-based therapeutic programs by providing comprehensive
off-target analysis services, powered by SeQure Dx’s GUIDE-seq
technology, alongside IDT’s award-winning rhAmpSeq™ CRISPR Analysis
System.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240715086137/en/
Integrated DNA Technologies (IDT), a
global leader in CRISPR genome editing solutions, inked a licensing
agreement with SeQure Dx, a company focused on off-target analysis
for preclinical and clinical gene modification customers,
bolstering IDT’s complete CRISPR portfolio comprised of world-class
RUO to CGMP solutions from design to analysis. (Graphic: Business
Wire)
“Off-target effects continue to be a primary concern in genome
editing and are still not fully understood,” said Sandy Ottensmann,
VP/General Manager, Gene Writing & Editing Business Unit at
IDT. “With an increasing pipeline of CRISPR-based therapeutics that
are entering and progressing in trials, the delivery of safer and
more efficient genome editing platforms to the clinic becomes
paramount. IDT’s expanded off-target analysis capabilities
demonstrate a transformational shift we are making to support cell
and gene therapy developers in their transition to the clinic, in a
drive to make life-changing therapies as safe as possible.”
Dr. Keith Joung, Scientific Founder of SeQure Dx, added,
“SeQure's best-in-class off-target nomination and confirmation
platforms will seamlessly complement IDT’s CRISPR-based portfolio
of products and services. By combining SeQure’s & IDT’s
innovative technologies, this will enhance precision and safety in
gene editing, bringing transformative solutions to researchers and
patients worldwide.”
The licensing agreement with SeQure Dx expands IDT’s
comprehensive off-target analysis capabilities by providing the
company access to SeQure Dx’s next generation sequencing-based gene
editing off-target analysis technology, GUIDE-seq. Originally
developed by Keith Joung’s group at Massachusetts General Hospital,
GUIDE-seq is a widely used off-target nomination assay, making it
an excellent starting point for developing and evaluating
CRISPR-focused therapeutics. Broadly used by academic researchers,
biotechs, large pharma and biopharma companies to help characterize
potential off-target events in their genome editing results,
GUIDE-seq provides genome-wide, unbiased identification of
double-stranded breaks by sequencing. It has contributed in part to
the successful development and release of multiple
therapeutics.
IDT’s CRISPR Innovation Journey
Last year, to help address development and manufacturing
challenges in a capacity-constrained market for CGMP/Q7 services,
IDT opened a therapeutic oligonucleotide manufacturing facility in
the U.S. to support the increased demand for high-quality cell and
gene therapy components. These critical reagents are foundational
to delivering on the promise of therapies to patients and are key
to accelerating the path to clinic for developers.
With IDT’s proprietary rhAmpSeq CRISPR Analysis System,
regulatory expertise, RUO to CGMP manufacturing capabilities, and
dedicated support team, customers can expect differentiated
off-target analysis services from a single provider for their
CRISPR therapeutic development. Launched in 2021, IDT’s rhAmpSeq
CRISPR Analysis System is an end-to-end solution for characterizing
and quantifying the full array of on- and off-target genome editing
events in CRISPR research products. The novel tool, endorsed by
renowned scientists, continues to grow in popularity as an assay
for off-target confirmation, and enables the robust analysis of
resulting next generation sequencing data. For more information
about IDT’s comprehensive off-target analysis services and
capabilities, visit
https://go.idtdna.com/OTE-analysis-request-consult.
About IDT
For more than 35 years, Integrated DNA Technologies, Inc.
(IDT) has been empowering genomics laboratories with an
oligonucleotide manufacturing process unlike anyone else in the
industry, with the most advanced synthesis, modification,
purification, and quality control capabilities available. Since its
founding in 1987, IDT has progressed from a leading oligo
manufacturer to a genomics solutions provider supporting key
application areas such as next generation sequencing, CRISPR genome
editing, synthetic biology, digital PCR, and RNA interference. IDT
manufactures products used by scientists researching many forms of
cancer and most inherited and infectious diseases.
Seeking to fulfill its mission of accelerating the pace of
genomics, IDT acquired Archer™ NGS Research Assays in December
2022. When combined with its existing solutions, the expanded
portfolio helps realize the shared vision of enabling researchers
to rapidly move from the lab to life-changing advances.
IDT’s infrastructure supports customers around the globe with
its manufacturing headquarters situated in Coralville, Iowa, USA,
with additional manufacturing sites in San Diego, California, USA;
Boulder, Colorado, USA; Research Triangle Park, North Carolina,
USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore.
IDT is proud to be part of Danaher. Danaher’s science and
technology leadership puts IDT’s solutions at the forefront of the
industry, so they can reach more people. Being part of Danaher
means we can offer unparalleled breadth and depth of expertise and
solutions to our customers.
Together with Danaher’s other businesses across Biotechnology,
Diagnostics and Life Sciences, we unlock the transformative
potential of cutting-edge science and technology to improve
billions of lives every day.
For more information about IDT, visit www.idtdna.com and follow
the company on LinkedIn, X, Facebook, YouTube, and Instagram.
Disclaimer: CGMP refers to products manufactured under
ICHQ7; IDT engineering runs and CGMP gRNA are for development
and investigational use only. The performance characteristics of
this product have not been established. This product is not
intended to be used as final drug product. The purchaser is solely
responsible for all decisions regarding the intended use of the
product and any associated legal or regulatory obligations.
RUO—For research use only. Not intended for use in diagnostic,
investigational and/or therapeutic applications. Unless otherwise
agreed to in writing, IDT does not intend these products to be used
in clinical applications and does not warrant their fitness or
suitability for any clinical diagnostic use. Purchaser is solely
responsible for all decisions regarding the use of these products
and any associated regulatory or legal obligations.
About SeQure Dx
SeQure Dx is a genomics intelligence company dedicated to the
advancement of gene editing and cell therapies from discovery to
patient. SeQure’s initial preclinical platforms for the biopharma
industry, NoteSeQ and ScopeSeQ, comprise a suite of proprietary,
best-in-class diagnostic assays and bioinformatic analytics that
span the spectrum of off-target nomination and confirmation. The
NoteSeQ and ScopeSeQ platforms comprehensively solve our partners’
preclinical off-target evaluation needs, including guide selection
and IND submissions. SeQure Dx’s goal is to help ensure that gene
editing and cell therapies are developed for all patients who would
benefit from this next generation of life-saving technologies. For
more information, please visit https://sequre-dx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240715086137/en/
Kristina Sarenas Director of PR 800-328-2661 (USA & Canada)
+1 319-626-8400 (outside USA) idtpr@idtdna.com
Joe Mohr Senior Director of Business Development
joe.mohr@sequre-dx.com